Publication

Article

Pharmaceutical Technology

Pharmaceutical Technology-03-02-2003
Volume27
Issue 3

Effects of Breadfruit and Cocoyam Starch Mucilage Binders. On Disintegration and Dissolution Behaviors of Paracetamol Tablet Formulations.

Author(s):

A.S. Adebayo, PhD

Binder properties of mucilage of starches extracted from breadfruit and cocoyam were investigated in paracetamol tablet formulations using tablet physical properties, disintegration times, and dissolution rates as assessment parameters.

External Link - article-49252.pdf

Articles in this issue
The Clarification of Bioreactor Cell Cultures for Biopharmaceuticals
Standards for Supplements
Concept Paper Discusses Update of Aspetic Processing Guidelines
Outsourcing Outlook March 2003
A Review of Classification of Emerging Excipients in Parenteral Medications
March 2003
Effects of Breadfruit and Cocoyam Starch Mucilage Binders. On Disintegration and Dissolution Behaviors of Paracetamol Tablet Formulations.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!
Related Videos
Drug Digest: Patient Preference Drives Solid Dosage Trends
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Related Content
Young man having asthma attack or choking suffering from respiration problems | Image Credit: © Feodora - stock.adobe.com
July 18th 2025

UK Anaphylaxis Nasal Spray Approval Helps Reshape Emergency Allergy Treatment

Christopher Cole
Newly approved needle-free adrenaline spray offers longer shelf life, better stability, and easier use, signaling a shift in emergency drug delivery design.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024

Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development

In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
The mRNA or messenger Ribonucleic Acid white text for medical or outbreak concept 3d rendering | Image Credit: ©niphon - adobe.stock.com
June 24th 2025

Looking Beyond mRNA-based COVID-19 Vaccines to Innovative Therapeutics

Cheryl Barton
mRNA technologies offer great promise in immunotherapy and non-immunogenic applications.
Drug Solutions Podcast: mRNA Past, Present, and Future
August 17th 2023

Drug Solutions Podcast: mRNA Past, Present, and Future

Chris Spivey
An mRNA conversation about the recent past, current hot topics, and probable future.
Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com
March 25th 2025

AstraZeneca and Alteogen Sign License Agreement for Developing Subcutaneous Formulations of Oncology Assets

Feliza Mirasol
Under the agreement, AstraZeneca will use Alteogen’s proprietary hyaluronidase platform technology to develop and commercialize subcutaneous formulations of multiple oncology assets in its portfolio.
Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - stock.adobe.com
March 12th 2025

FDA Approves First Generics of Rivaroxaban Tablets

Patrick Lavery
Rivaroxaban, long known under the brand name Xarelto, is an anticoagulant, a classification that is among the most-prescribed medications in the United States.